Zymergen, Inc.

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.

Are you a current or former employee of the company?*YesNo


+Additional Purchases


+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:

There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Portnoy Law Firm
Lesley F. Portnoy, Esq.,
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067

It is alleged in this lawsuit that Zymergen’s Registration Statement was misleading and false and omitted to state that: (i) key customers had encountered technical issues, during the qualification process for Hyaline, including product shrinkage and incompatibility with customers’ processes; (ii) though the qualification process was critical in achieving market acceptance for Hyaline, as well as generating revenue, Zymergen lacked visibility into the qualification process; (iii) Zymergen overestimated demand for its products, as a result; and (iv) consequently, Zymergen’s product delivery timeline was reasonably likely to be delayed, in turn delaying generation of revenue..